NewAmsterdam Pharma Company NAMS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$48.44M+35.3% | -$74.92M-4.1% | -$72.01M-315% | -$17.36M+56.1% | -$39.53M+57.1% | ||
| $62K+5.1% | $59K-7.8% | $64K+42.2% | $45K-13.5% | $52K+2.0% | ||
| $18M+28.4% | $14.02M-6.6% | $15.01M-1.1% | $15.18M-0.2% | $15.21M+61.6% | ||
| $10K+142% | -$24K+93.9% | -$396K+16.1% | -$472K+8.0% | -$513K-804% | ||
| -$12K-9.1% | -$11K-1,000% | -$1K— | —— | —— | ||
| -$793K-115% | $5.32M+334% | -$2.27M— | $0-100% | $2.25M+170% | ||
| -$10.33M-294% | $5.32M— | —— | —— | -$4.95M-307% | ||
| —— | —— | —— | -$3.03M-1.7% | -$2.98M— | ||
| -$30.6M+25.1% | -$40.88M-24.7% | -$32.77M+13.0% | -$37.67M-3.3% | -$36.47M+2.7% | ||
| $38K-62.0% | $100K+138% | $42K-52.3% | $88K+450% | $16K+433% | ||
| -$11.51M+45.6% | -$21.14M— | $0+100% | -$159.14M-5,674% | $2.86M+105% | ||
| $10.41M-16.7% | $12.5M+123% | $5.62M+64.1% | $3.42M-56.8% | $7.92M+524% | ||
| $11.07M-19.1% | $13.68M+132% | $5.89M+72.0% | $3.43M-47.5% | $6.52M-98.6% | ||
| -$1.33M— | $0-100% | $222K-97.5% | $8.83M+134% | $3.77M+148% | ||
| -$31.05M+35.8% | -$48.33M-98.3% | -$24.37M+87.4% | -$193.38M-614% | -$27.09M-108% | ||
| —— | —— | —— | —— | —— | ||
| $10K+142% | -$24K+93.9% | -$396K+16.1% | -$472K+8.0% | -$513K-804% | ||
| -$5.94M-139% | $15.34M-35.5% | $23.79M+1,019% | -$2.59M+85.4% | -$17.75M-139% | ||
| -$1.61M— | $0-100% | $218K-97.5% | $8.63M+101% | $4.29M+155% | ||
| -$12K-9.1% | -$11K-1,000% | -$1K— | —— | —— | ||
| -$10.33M-294% | $5.32M— | —— | —— | -$4.95M-307% | ||
| —— | —— | —— | -$3.03M-1.7% | -$2.98M— | ||
| -$15.22M-251% | $10.06M— | —— | $21.86M+236% | -$16.03M-284% | ||
| -$16K— | —— | —— | —— | $3K-25.0% | ||
| —— | —— | —— | —— | $1.59M— | ||
| $651K-44.8% | $1.18M+331% | $274K+27,300% | $1K-99.5% | $183K-46.2% | ||
| -$1.33M— | $0-100% | $222K-97.5% | $8.83M+134% | $3.77M+148% | ||
| —— | —— | —— | —— | $40.81M— | ||
| —— | —— | —— | —— | —— | ||
| -$30.64M+25.2% | -$40.98M-24.9% | -$32.81M+13.1% | -$37.76M-3.5% | -$36.48M+2.7% | ||
| -$30.64M+25.2% | -$40.98M-24.9% | -$32.81M+13.1% | -$37.76M-3.5% | -$36.48M+2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's cash flow data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.